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Abstract
 
Recognition of human erythrocytes by 
 
Plasmodium
 
 species depends in part on Region II of the
Duffy binding-like family of parasite ligands, which includes BA erythrocyte binding ligand
(BAEBL) of 
 
P.
 
 
 
falciparum
 
. In previous studies of BAEBL from two clones, Dd2/Nm from Viet-
nam and E12 from Papua New Guinea (PNG), it was found that BAEBL bound different
erythrocyte receptors. Because of variation in binding specificity, we studied the sequence and
erythrocyte binding specificity of Region II of BAEBL in 
 
P. falciparum
 
 clones from different
parts of the world. We observed five nucleotide substitutions leading to five amino acid
changes and five polymorphisms in Region II of BAEBL in parasites from both PNG and other
parts of the world. We expressed four of the polymorphisms on COS cells and determined
their binding to enzyme-treated erythrocytes and to Gerbich-negative erythrocytes. We also
performed erythrocyte-binding assay using the native protein from radiolabeled culture super-
natant. Both assays demonstrated that each of the four polymorphisms in the parasite ligand,
BAEBL, bound to a different receptor on erythrocytes. These results suggest that 
 
P. falciparum
 
has evolved multiple invasion pathways dependent on polymorphisms in the BAEBL ligand.
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Introduction
 
The binding of merozoites from 
 
Plasmodium
 
 species to
erythrocytes is dependent on two families of parasite
ligands, the Duffy binding-like (DBL) and the reticulocyte
binding-like (RBL) (1–3). Both are named for the erythro-
cyte receptors for 
 
Plasmodium vivax
 
: the Duffy blood group
proteins and a reticulocyte-specific receptor (4). Unlike 
 
P.
vivax
 
 that is limited to Duffy positive reticulocytes, 
 
Plasmo-
dium falciparum
 
 has greater flexibility in its invasion path-
ways (5). 
 
P. falciparum
 
 invades all aged erythrocytes; no hu-
man erythrocytes are known to be refractory to all 
 
P.
falciparum
 
 clones. This flexibility is believed to result, in
part, from multiple copies of DBL and RBL genes in 
 
P. fal-
ciparum
 
 (5). The erythrocyte specificities of the DBL and
RBL genes are completely different for 
 
P. falciparum
 
 than
for 
 
P. vivax
 
. The DBL family in 
 
P. falciparum
 
 includes
erythrocyte binding antigen-175 (EBA-175) and its para-
logue, BA erythrocyte binding ligand (BAEBL; reference
1). Whereas EBA-175 bound only glycophorin A (6),
BAEBL from two clones of 
 
P. falciparum
 
 had different
erythrocyte receptors (7, 8). One clone, Dd2/Nm from
Vietnam, failed to bind trypsin-treated erythrocytes and
Gerbich-negative erythrocytes (7), a common human mu-
tation of glycophorin C/D in Papua New Guinea (PNG;
references 9 and 10). Another clone, E12 from PNG,
bound to trypsin-treated erythrocytes, indicating that it
 
used a receptor other than glycophorin C/D (8). One
possibility was that the variation in receptors could result
from mutations in BAEBL selected in PNG. Therefore we
sequenced the erythrocyte binding domain of BAEBL
(Region II) from multiple clones of 
 
P. falciparum
 
 isolated
from PNG and from other parts of the world and deter-
mined the effect of polymorphisms in Region II of BAEBL
on its erythrocyte binding specificity.
 
Materials and Methods
 
Parasite Clones Studied.
 
The isolates used in this study were
obtained from Papua New Guinea: PNG 2, 3, 4, 13 (11), 5, 9–1,
9–3 and 10–1 (a gift from Russell Howard, Maxygen Corp.,
Redwood City, CA), 1917 and 1905 (a gift from Karen Day,
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Oxford University, Oxford, UK), E12 (12); from Africa: 3D7
isolated from the Amsterdam airport (13) but has microsatellites
of an African parasite, M24, Fab9, Sc/D6; from South America:
PC49, 7G8, DIV30, PC26 (11), HB3(14); and from Asia: Camp,
T2/C6, MT/S-1, Dd2 (11), Dd2/Nm (15). Genotypes of the
parasite lines were confirmed by microsatellite analysis (16). Para-
site culture and DNA isolation were performed as described pre-
viously (17). Two 
 
P. falciparum
 
 clones, HB3 and Camp, were
used for the erythrocyte binding assay described below.
 
Sequence Analysis of BAEBL Genes.
 
Open reading frame se-
quences of BAEBL were amplified from genomic DNA. Oligo-
nucleotide primer sequences were 5
 
 
 
-TATCGTTTTTTTATGA
GCAT-3
 
 
 
 
 
and 5
 
 
 
-GTCAGAATAGGTACAATATT-3
 
 
 
. After
treatment with SAP/
 
Exo
 
I (United States Biochemical Corp.),
polymerase chain reaction products were directly sequenced us-
ing BigDye terminator chemistry on an ABI3100 sequencer (Ap-
plied Biosystems). DNA sequences were aligned using Se-
quencher 3.1 (Gene Codes Corp.) or AssemblyLIGN software
(Oxford Molecular Ltd.).
 
Expression of Region II and its F1 and F2 Subregions on COS7
Cells.
 
Region II of BAEBL was cloned into the T8 vector (18).
This vector contains a signal sequence and a glycosylphosphati-
dylinositol anchor that attaches the fusion protein to the surface of
COS7 cells. Insertion of the variant sequences was accom-
plished by amplification with forward primer (5
 
 
 
-
CGTGCGGCCGCCAATATACGTTTATACAGAAACG-
TACTCATTTGTTTGCT-3
 
 
 
) and reverse primer (5
 
 
 
-AG-
TGAATTCTATATCGTGTTTTGTTTTAGGATATTTA-3
 
 
 
)
to generate the NotI and EcoRI sites, respectively. Insertion
of the F1 subregion of BAEBL from 
 
P. falciparum
 
 clone Dd2/
Nm was accomplished with forward primer (5
 
 
 
-
CGTGCGGCCGCCAATATACGTTTATACAGAAACGTA
CTCATTTGTTTGCT-3
 
 
 
) and reverse primer (5
 
 
 
-AGTG-
AATTCGCAATCACATAAATCATCATATTCCTTTTCAT
TTTTG-3
 
 
 
). Insertion of the F2 subregion of BAEBL 
 
P. falci-
parum
 
 clone Dd2/Nm was accomplished with forward primer
(5
 
 
 
-CGTGCGGCCGCAGATATACTGCTACTATTATTAA-
AAGTTTTCTAAATGGTC-3
 
 
 
) and reverse primer (5
 
 
 
-AG-
TGAATTCTATATCGTGTTTTGTTTTAGGATATTTA-3
 
 
 
).
After a hot start at 94
 
 
 
C for 2 min, samples were cycled 30 times
at 94
 
 
 
C for 30 s, 55
 
 
 
C for 50 s, and 72
 
 
 
C for 3 min, followed by
a final 10-min incubation at 72
 
 
 
C. DBL2, a Duffy-like domain of
 
P. falciparum 
 
erythrocyte membrane protein 1 (PfEMP-1), cloned
in the T8 vector was used as a negative control in every experi-
ment for the erythrocyte binding assay (19). This domain is ex-
pressed on the surface of COS7 cells and never binds erythro-
cytes.
 
Cell Culture and Transfection of COS7 Cells.
 
COS7 cells (Ameri-
can Type Culture Collection) were cultured in DMEM with 10%
fetal calf serum (Invitrogen) in a humidified 5% CO
 
2
 
 incubator at
37
 
 
 
C. Cells (1.5 
 
 
 
 10
 
5
 
) were seeded at 30% confluency onto 12-
mm diameter glass coverslips of thickness between 0.13 and 0.17
mm (Fisher Scientific) in 3.5-cm diameter wells and transfected
with 5 
 
 
 
g of plasmid DNA by the calcium phosphate precipita-
tion method (20). The cells were washed three times with PBS
12–16 h after transfection. The transfected cells were used for im-
munofluorescence or erythrocyte binding assays 48 h after trans-
fection.
 
Enzyme Treatment of Erythrocytes.
 
Whole blood was collected
in 10% citrate phosphate dextrose and stored at 4
 
 
 
C. The eryth-
rocytes were washed three times in RPMI 1640 (Invitrogen)
containing 25 mM HEPES and 0.36 mM hypoxantine, pH 7.4
(Sigma-Aldrich) before being treated twice in 25 U of
neuraminidase (
 
Vibrio cholerae
 
; Calbiochem) in RPMI 1640 for
2 h at 37
 
 
 
C. Erythrocytes were treated twice with 1 mg/ml of
trypsin-TPCK (Sigma-Aldrich) for 2 h at 37
 
 
 
C. Trypsin activity
was inhibited with 1 mg/ml soybean trypsin inhibitor (Sigma-
Aldrich). Treated erythrocytes were resuspended to an hematocrit
of 10% in DMEM with 10% fetal calf serum.
 
Erythrocyte Binding Assay to Transfected COS7 Cells.
 
A 10%
erythrocyte suspension (40 
 
 
 
l) was added to transfected COS7
cells grown on coverslips (21). The erythrocytes were allowed to
settle for 2 h at 37
 
 
 
C. The cells were washed by inversion of cov-
erslips onto a glass support for 20 min in PBS. Transfected COS7
cells were scored using an inverted microscope. Erythrocyte
binding assay was followed by an Immunofluorescence assay as
described below.
 
Immunofluorescence Assay.
 
Transfected cells were assayed for
surface expression 48 h after transfection. The cells were washed
in PBS and fixed in 3.7% formaldehyde for 5 min at room tem-
perature. This was followed by three washes in PBS for 5 min
each at room temperature and staining with mouse mAb 179 for
1 h at room temperature at a final concentration of 4.1 ng/
 
 
 
l.
The epitope is directed at an amino acid sequence in the T8 vec-
tor located at COOH terminus of Region II of BAEBL (18). Ex-
pression of Region II of BAEBL was also determined using the
rat polyclonal antibody generated against Region II (7). The cells
were washed three times for 5 min in PBS and visualized with
fluorescein-conjugated goat anti–mouse Ab or goat anti–rat
Alexa 488 (Jackson ImmunoResearch Laboratories/Molecular
Probes) at a dilution of 1:100 in 10% normal goat serum (Jackson
ImmunoResearch Laboratories). Excess secondary Ab was re-
moved by washing three times in PBS for 5 min and mounted
with Prolong Antifade (Molecular Probes).
 
Modified Erythrocyte Binding Assay.
 
Metabolically labeled su-
pernatant from 
 
P. falciparum
 
 clones HB3 and Camp were used in
absorption and elution assays described previously (7).
 
Results and Discussion
 
Initial characterization of erythrocyte receptors recog-
nized by BAEBL from two different 
 
P. falciparum
 
 clones in
two different laboratories suggested that each had a differ-
ent erythrocyte receptor (7, 8). We sequenced the 
 
baebl
 
gene from eight parasite clones and found polymorphisms
restricted to Regions I and II of the molecules (Gen-
Bank/EMBL/DDBJ accession nos. AF605832, AF605833,
AF605834, and AF424236). In total, we sequenced Re-
gions I and II of BAEBL from 11 clones from PNG and 14
clones from other parts of the world where 
 
P. falciparum
 
malaria is endemic. We observed five different sequence
variants in Region II with polymorphisms in four amino
acid positions (Table I). Four of the same sequence variants
occurred in PNG as in the rest of the world (Table I). Be-
cause 
 
P. falciparum
 
 populations in PNG are isolated and
there is no evidence of population admixture with parasites
from other parts of the world (11), the BAEBL sequence
variants found in PNG are likely to be from independent
founder mutations.
Region II of 
 
P. falciparum
 
 DBL genes (1) is duplicated,
forming the F1 and F2 domains. All base substitutions in
Region II of BAEBL occurred in the F1 domain (Fig. 1).
EBA-175, another DBL gene of 
 
P. falciparum
 
, differed from 
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BAEBL in that mutations were scattered throughout both
the F1 and F2 domains (22; Fig. 1). We expressed sepa-
rately the F1 and the F2 region of BAEBL on the surface of
COS7 cells and failed to observe erythrocyte binding to ei-
ther region. As the sequence of F2 is conserved, it may be
that both domains are required for erythrocyte binding.
We investigated the functional significance of polymor-
phisms in the erythrocyte-binding domain (Region II) of
BAEBL. We expressed transiently Region II of four polymor-
phic sequences on the surface of COS cells with the T8 vector.
For all transfected constructs, positive surface expression was
confirmed by immunofluorescence with two antibodies: one
directed against the epitope on the COOH terminus of the
heterologous protein and the other directed against Region II
of BAEBL (7). Binding to the COS cells was performed with
normal and enzyme-treated (trypsin and neuraminidase) eryth-
rocytes and Gerbich-negative erythrocytes (exon 3 deletion of
glycophorin C/D). Each of the four polymorphisms led to a
different binding specificity as demonstrated by different bind-
ing patterns to enzyme-treated and Gerbich-negative erythro-
cytes (Fig. 2). Region II from Dd2/Nm (VSTK) was sensitive
to neuraminidase and trypsin and was the only sequence to
 
Table I.
 
Position of Amino Acid Polymorphisms in BAEBL from Different Malaria-endemic Regions
 
Region I
 
a
 
Region II
 
a
 
Clones 112 185 239 261 285
Papua New Guinea
PNG2, PNG9-1 L(CTT) V(GTT) S(AGT)
 
T
 
(A
 
C
 
G) K(AAA)
PNG4, PNG9-3, 1917, 1905 L(CTT) V(GTT) S(AGT) K(AAG) K(AAG)
PNG13
 
F
 
(
 
T
 
TT) V(GTT) S(AGT) K(AAG) K(AAG)
PNG5, PNG10-1 L(CTT)
 
I
 
(
 
A
 
TT) S(AGT) K(AAG) K(AAA)
E12
 
F
 
(
 
T
 
TT)
 
I
 
(
 
A
 
TT) S(AGT) K(AAG) K(AAA)
PNG3
 
F
 
(
 
T
 
TT)
 
I
 
(
 
A
 
TT)
 
N
 
(
 
A
 
AT)
 
R
 
(A
 
G
 
G)
 
E
 
(
 
G
 
AA)
Other areas of the world
Dd2, Dd2/Nm (Vietnam)
7G8, DIV30 (Brazil)
PC26 (Peru)
L(CTT) V(GTT) S(AGT)
 
T
 
(A
 
C
 
G) K(AAA)
Sc/D6 (Sierra Leone)
HB3 (Honduras)
L(CTT) V(GTT) S(AGT) K(AAG) K(AAA)
MT/S-1
 
F
 
(
 
T
 
TT)
 
I
 
(
 
A
 
TT) S(AGT) K(AAG) K(AAA)
M24 (Kenya), 3D7 (Africa)
PC49 (Peru), T2/C6
(Thailand)
 
F
 
(
 
T
 
TT)
 
I(ATT) N(AAT) K(AAG) K(AAA)
Fab9 (Kwazulu)
Camp (Malaysia)
L(CTT) I(ATT) N(AAT) R(AGG) E(GAA)
Polymorphisms in bases and amino acids are shown in bold.
aFor Regions I and II, numbers refer to the amino acids in the sequence of BAEBL from GenBank/EMBL/DDBJ accession no. AF33918.
Figure 1. Location of poly-
morphisms in BAEBL and EBA-
175. Erythrocyte-binding domain
is duplicated into F1 (light gray)
and F2 (dark gray). Positions of
polymorphism in both BAEBL
(this study) and EBA-175 (refer-
ence 21) are highlighted.1526 RBC Receptors and Polymorphisms in P. falciparum Ligand
bind poorly to Gerbich-negative erythrocytes; the other three
sequences bound equally well to Gerbich-negative erythro-
cytes as to normal erythrocytes. At least three other patterns of
binding specificity were observed: clone E12 (ISKK) bound
trypsin-treated but not neuraminidase-treated erythrocytes;
PNG3 (INRE) bound both neuraminidase- and trypsin-
treated erythrocytes; and HB3 (VSKK) bound neuraminidase-
but not trypsin-treated erythrocytes. We showed that a single
base change leading to a single amino acid substitution in the
erythrocyte-binding domain of BAEBL led to recognition of
different molecules on human erythrocytes (VSTK to VSKK
and VSKK to ISKK).
We next determined whether the specificity of binding of
BAEBL observed on COS7 cells mirrors the binding of the na-
tive protein in culture supernatants. The E12 and Dd2/Nm se-
quences were derived from parasite clones that had been stud-
ied previously (7, 8). BAEBL immunoprecipitated from
culture supernatants of E12 and Dd/Nm bound to erythrocytes
with the specificity identical to that described for Region II ex-
pressed on COS cells, indicating that the two assays are measur-
ing the same specificity (7, 8). Furthermore, BAEBL in culture
supernatants from HB3 (VSKK) and Camp (INRE) clones also
had identical binding specificities to enzyme treated erythro-
cytes as Region II of the corresponding sequences expressed on
COS cells (Fig. 3). The BAEBL variant from HB3 (VSKK)
was not absorbed to neuraminidase-treated erythrocytes but
was absorbed to trypsin-treated erythrocytes (unpublished
data). Likewise, BAEBL variant from Camp (INRE) was not
absorbed to either neuraminidase- or trypsin-treated erythro-
cytes (unpublished data). Thus, like Duffy of P. vivax (21) and
EBA-175 of P. falciparum (6), Region II of BAEBL defines the
erythrocyte binding specificity of the native protein.
Such polymorphism in sequence and receptors was de-
scribed for influenza hemagglutinin selected for binding to
sialic acid linked to galactose by  2,6 instead of  2,3 (23).
The change in receptor specificity was caused by a point
mutation that led to a single amino acid change in the re-
ceptor pocket. The amino acid changes that we have noted in
BAEBL that led to changes in receptor specificity may be lo-
cated in the receptor pocket, although the structure of Region
II of BAEBL has yet to be solved. Mutations in Region II
of EBA-175 do not affect its requirement for sialic acid
(21). As EBA-175 only binds sialic acid in the context of
glycophorin A (6), it remains to be determined whether
mutations in EBA-175 affect binding to glycophorin A.
Other highly polymorphic merozoite proteins such as api-
cal membrane antigen 1 (AMA1) may encode variation in
receptors, but these polymorphisms as for EBA-175 are
more likely to play a role in immune evasion (21, 24, 25).
Members of multigene families (e.g., the DBL family of
P. falciparum, the P. yoelii family of 230-kD proteins, and
the var family of genes) have evolved new functions
through gene duplication (6, 7, 26–30). Here, we describe
the ability of a single P. falciparum gene to recognize various
erythrocyte receptors depending on polymorphisms in the
erythrocyte-binding domain.
Why has the parasite evolved to have such diversity? What is
the advantage to the parasite to have multiple niches with dif-
ferent erythrocyte receptors? In PNG, an area of 50% allelic
frequency of Gerbich-negative erythrocytes (9, 10), this diver-
sity may allow the parasite to survive despite this human muta-
tion in a BAEBL receptor. BAEBL polymorphisms occurred,
however, in other regions besides PNG. Several possibilities
may explain the diversity in receptors. First, Gerbich-negative
Figure 2. Binding patterns of BAEBL variants to enzyme-treated and
Gerbich-negative erythrocytes. Region II of BAEBL expressed in COS
cells is from amino acid 143 to 606 (GenBank/EMBL/DDBJ accession
no. AF332918) and contains the mutations shown at the positions delin-
eated in Table I. COS cells with five or more attached RBCs were
counted and the total per coverslip recorded. Data are shown as the mean
of three independent experiments, and the error bar is the standard devia-
tion. Data from enzyme-treated and Gerbich-negative erythrocytes are ex-
pressed as the percentage of binding to normal, untreated erythrocyte. The
control normal untreated erythrocyte samples contained between 30 and
120 COS cells with bound erythrocytes. Two controls were included in
each experiment; untransfected COS cells as well as COS cells transfected
with DBL2, a domain in the adhesion molecule PfEMP1, expressed in the
T8 vector did not bind either untreated or enzyme-treated erythrocytes.
Figure 3. Immunoprecipitation of BAEBL eluted from untreated and
enzyme treated erythrocytes. BAEBL immunoprecipitated from superna-
tant of P. falciparum clone HB3 (VSKK; A) and P. falciparum clone Camp
(INRE; B) has similar binding characteristics as Region II of the corre-
sponding BAEBL variants expressed on COS cells (see Fig. 2). The mo-
lecular weight standard is shown on the left.1527 Mayer et al. Brief Definitive Report
cells may occur at high frequency in other parts of the world.
This human polymorphism may have been missed because few
reagents exist for detecting the Gerbich blood group, and they
are all in private collections. In addition, there is little interest in
this blood group system because variation does not cause eryth-
roblastosis fetalis and is not responsible for transfusion reactions.
With the availability of molecular tools to identify deletions in
exon 3 that define the Gerbich-negative phenotype (10), it is
now possible to determine whether this mutation has been
missed in other malarious areas. Second, other mutations in
glycophorin C/D may occur in other endemic areas.
A third possibility is that the polymorphism in parasite
ligands has an advantage unrelated to Gerbich-negative hu-
man erythrocytes. Polymorphisms in erythrocyte-binding
ligands may provide the parasite population versatility in
the invasion pathways, thus increasing P. falciparum fitness.
Our data suggest three other erythrocyte receptors for
BAEBL besides the Gerbich blood group antigen. It is pos-
sible that polymorphisms also exist in these other BAEBL
erythrocyte receptors. Polymorphisms in these may have
driven the variation seen in BAEBL. This question awaits
the identification of these erythrocyte receptors.
P. falciparum has evolved great flexibility in its invasion
pathways. In part, this may result from the multiple copy
DBL family of erythrocyte binding ligands, three of which
have different erythrocyte receptor specificities (6, 7, and
unpublished data). This is in contrast to P. vivax, which has
a single copy of the DBL family that recognizes the Duffy
blood group proteins, explaining the resistance to P. vivax
infection in West Africa, where humans lack the Duffy
blood group proteins on their erythrocytes. In addition to
the multiple copies of DBL, we now describe another
mechanism for recognition of different molecules on the
erythrocytes by various forms of a single P. falciparum eryth-
rocyte binding ligand.
Submitted: 9 May 2002
Revised: 8 October 2002 
Accepted: 14 October 2002
References
1. Adams, J.H. O. Kaneko, P.L. Blair, and D.S. Peterson. 2001.
An expanding ebl family of Plasmodium falciparum. Trends Par-
asitol. 17:297–299.
2. Galinski, M.R., C. Corredor-Medina, P. Ingravello, and
J.W. Barnwell. 1992. A reticulocyte-binding protein com-
plex of Plasmodium vivax merozoites. Cell. 69:1213–1226.
3. Galinski, M.R., and J.W. Barnwell. 1996. Plasmodium vivax:
Merozoites, invasion of reticulocytes and considerations for
malaria vaccine development. Parasitol. Today. 12:20–29.
4. Adams, J.H., B.H.K. Sim, S.A. Dolan, X. Fang, D.C. Kaslow,
and L.H. Miller. 1992. A family of erythrocyte binding proteins
of malaria parasites. Proc. Natl. Acad. Sci. USA. 89:7085–7089.
5. Miller, L.H., D.I. Baruch, K. Marsh, and O.K. Doumbo.
2002. The pathogenic basis of malaria. Nature. 415:673–679.
6. Sim, B.K.L., C.E. Chitnis, K. Wasnioswska, T.J. Hadley, and
L.H. Miller. 1994. Receptor and ligand domains for invasion of
erythrocytes by Plasmodium falciparum. Science. 264:1941–1944.
7. Mayer, D.C.G., O. Kaneko, D.E. Hudson-Taylor, M.E.
Reid, and L.H. Miller. 2001. Characterization of a Plasmo-
dium falciparum erythrocyte-binding protein paralogous to
EBA-175. Proc. Natl. Acad. Sci. USA. 98:5222–5227.
8. Thompson, J.K., T. Triglia, M.B. Reed, and A.F. Cowman.
2001. A novel ligand from Plasmodium falciparum that binds to
a sialic acid-containing receptor on the surface of human
erythrocytes. Mol. Microbiol. 41:47–58.
9. Booth, P.B., D. Tills, A. Warlow, A.C. Kopec, A.E. Mou-
rant, P. Teesdale, and R.W. Hornabrook. 1982. Red cell an-
tigen, serum protein and red cell enzyme polymorphisms in
Karkar Islanders and inhabitants of the adjacent North Coast
of New Guinea. Hum. Hered. 32:385–403.
10. Patel, S., R.K. Mehlotra, W. Kastens, C.S. Mgone, J.W. Kazura,
and P.A. Zimmerman. 2001. The association of the glycophorin
C exon 3 deletion with ovalocytosis and malaria susceptibility in
Wosera, Papua New Guinea. Blood. 98:3489–3491.
11. Wootton, J.C., X. Feng, M.T. Ferdig, R.A. Cooper, J. Mu,
D.I. Baruch, A.J. Magill and X.Z. Su. 2002. Genetic diver-
sity and chloroquine selective sweeps in Plasmodium falci-
parum. Nature. 418:320–323.
12. Anders, A.F., G.V. Brown, and A. Edwards. 1983. Characteriza-
tion of an S antigen synthesized by several isolates of Plasmodium
falciparum. Proc. Natl. Acad. Sci. USA. 80:6652–6656.
13. Walliker, D., I.A. Quakyi, T.E. Wellems, T.F. McCutchan,
A. Szarfman, W.T. London, L.M. Corcoran, T.R. Burkot,
and R. Carter. 1987. Genetics analysis of the human malaria
parasite Plasmodium falciparum. Science. 236:1661–1666.
14. Bhasin, V.K., and W. Trager. 1984. Gametocyte-forming
and non-gametocyte-forming clones of Plasmodium falci-
parum. Am. J. Trop. Med. Hyg. 33:534–537.
15. Dolan, S.A., L.H. Miller, and T.E. Wellems. 1990. Evidence
for a switching mechanism in the invasion of erythrocytes by
Plasmodium falciparum. J. Clin. Invest. 86:618–624.
16. Su, X.Z., D.J. Carucci, and T.E. Wellems. 1998. Plasmodium
falciparum: parasite typing by using a multicopy microsatellite
marker, PfRRM. J. Exp. Parasitol. 89:262–265.
17. Su, X.Z., L.A. Kirkman, H. Fujioka, and T.E. Wellems.
1997. Complex polymorphisms in an approximately 330 kDa
protein are linked to chloroquine-resistant falciparum in
Southeast Asia and Africa. Cell. 91:593–603.
18. Buffet, P.A., B. Gamain, C. Scheidig, D. Baruch, J.D. Smith,
R. Hernandez-Rivas, B. Pouvelle, S. Oishi, N. Fujii, T. Fu-
sai, et al. 1999. Plasmodium falciparum domain mediating ad-
hesion to chondroitin sulfate A: a receptor for human placen-
tal infection. Proc. Natl. Acad. Sci. USA. 96:12743–12748.
19. Su, X.Z., V.M. Heatwole, S.P. Wertheimer, F. Guinet, J.A.
Herrfeldt, D.S. Peterson, J.A. Ravetch, and T.E. Wellems.
1995. The large diverse gene family var encodes protein that
are involved in cytoadherence and antigenic variation of Plas-
modium falciparum-infected erythrocytes. Cell. 82:89–100.
20. Graham, F.L., and A.J. van der Eb. 1973. A new assay of in-
fectivity of human adenovirus 5 DNA. Virology. 52:456–467.
21. Chitnis, C.E., and L.H. Miller. 1994. Identification of the
erythrocyte binding domains of Plasmodium vivax and Plasmo-
dium knowlesi proteins involved in erythrocyte invasion. J.
Exp. Med. 180:497–506.
22. Liang, H., and B.K. Sim. 1997. Conservation of structure and
function of the erythrocyte-binding domain of Plasmodium
falciparum EBA-175. Mol. Biochem. Parasitol. 84:241–245.
23. Rogers, G.N., J.C. Paulson, R.S. Daniels, J.J. Shekel, I.A. Wilson,
and D.C. Wiley. 1983. Single amino acid substitutions in influ-
enza haemagglutinin change receptor binding specificity. Nature.
304:76–78.1528 RBC Receptors and Polymorphisms in P. falciparum Ligand
24. Crewther, P.E., M.L. Matthew, R.H. Flegg, and R.F.
Anders. 1996. Protective immune responses to apical mem-
brane antigen 1 of Plasmodium chabaudi involve recognition of
strain-specific epitopes. Infect. Immun. 64:3310–3311.
25. Marshall, V.M., L.-X. Zhang, R.F. Anders, and R.L. Cop-
pel. 1996. Diversity of the vaccine candidate AMA-1 of Plas-
modium falciparum. Mol. Biochem. Parasitol. 77:109–113.
26. Ogun, S.A., and A.A. Holder. 1996. A highly molecular mass
P. yoelii rhoptry protein binds to erythrocytes. Mol. Biochem.
Parasitol. 76:321–324.
27. Smith, J.D., C.E. Chitnis, A.G. Craig, D.J. Roberts, D.E.
Hudson-Taylor, D.S. Peterson, and L.H. Miller. 1995.
Switches in expression of Plasmodium falciparum var genes cor-
relate with changes in antigenic and cytoadherent phenotypes
of infected erythrocytes. Cell. 82:101–110.
28. Baruch, D.I., J.A. Gormley, C. Ma, R.J. Howard, and B.L.
Paloske. 1996. Plasmodium falciparum erythrocyte membrane
protein 1 is a parasitized erythrocyte receptor for adherence
to CD36, thrombospondin, and intracellular adhesion mol-
ecule 1. Proc. Natl. Acad. Sci. USA. 93:3497–3502.
29. Rowe, A.J., J.M. Moulds, C.I. Newbold, and L.H. Miller.
1997. P. falciparum rosetting mediated by a parasite-variant
erythrocyte membrane protein and complement receptor 1.
Nature. 388:292–295.
30. Preiser, P.R., S. Khan, F.T. Costa, W. Jarra, E. Belnoue, S.
Ogun, A.A. Holder, T. Voza, I. Landau, G. Snounou, and L.
Renia. 2002. Stage-specific transcription of different reper-
toires of a multigene family during Plasmodium life cycle. Sci-
ence. 295:342–345.